NO325142B1 - Anvendelse av oligosakkarid for fremstilling av et medikament for forhindring av blodkoagulering i ekstra korporlige blodkretser - Google Patents
Anvendelse av oligosakkarid for fremstilling av et medikament for forhindring av blodkoagulering i ekstra korporlige blodkretser Download PDFInfo
- Publication number
- NO325142B1 NO325142B1 NO19995800A NO995800A NO325142B1 NO 325142 B1 NO325142 B1 NO 325142B1 NO 19995800 A NO19995800 A NO 19995800A NO 995800 A NO995800 A NO 995800A NO 325142 B1 NO325142 B1 NO 325142B1
- Authority
- NO
- Norway
- Prior art keywords
- sulfo
- glucopyranosyl
- deoxy
- sulfoamino
- methyl
- Prior art date
Links
- 229920001542 oligosaccharide Polymers 0.000 title claims abstract description 27
- 150000002482 oligosaccharides Chemical class 0.000 title claims abstract description 27
- 239000008280 blood Substances 0.000 title claims abstract description 13
- 210000004369 blood Anatomy 0.000 title claims abstract description 13
- 239000003814 drug Substances 0.000 title claims abstract description 13
- 230000023555 blood coagulation Effects 0.000 title claims abstract description 10
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 6
- 229940079593 drug Drugs 0.000 title claims description 11
- 108010074860 Factor Xa Proteins 0.000 claims abstract description 7
- 102000004411 Antithrombin III Human genes 0.000 claims abstract description 6
- 108090000935 Antithrombin III Proteins 0.000 claims abstract description 6
- 229960005348 antithrombin iii Drugs 0.000 claims abstract description 6
- 229940124639 Selective inhibitor Drugs 0.000 claims abstract description 4
- 238000000502 dialysis Methods 0.000 claims description 23
- 239000002253 acid Substances 0.000 claims description 12
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 12
- 150000003839 salts Chemical class 0.000 claims description 11
- 238000001631 haemodialysis Methods 0.000 claims description 6
- 230000000322 hemodialysis Effects 0.000 claims description 6
- 238000001990 intravenous administration Methods 0.000 claims description 5
- XEKSTYNIJLDDAZ-JASSWCPGSA-F fondaparinux sodium Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].O[C@@H]1[C@@H](NS([O-])(=O)=O)[C@@H](OC)O[C@H](COS([O-])(=O)=O)[C@H]1O[C@H]1[C@H](OS([O-])(=O)=O)[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](OS([O-])(=O)=O)[C@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O[C@@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](COS([O-])(=O)=O)O4)NS([O-])(=O)=O)[C@H](O3)C(O)=O)O)[C@@H](COS([O-])(=O)=O)O2)NS([O-])(=O)=O)[C@H](C(O)=O)O1 XEKSTYNIJLDDAZ-JASSWCPGSA-F 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims description 2
- 108090000190 Thrombin Proteins 0.000 description 6
- XEKSTYNIJLDDAZ-JASSWCPGSA-D decasodium;(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5r,6r)-6-[(2r,3s,4s,5r,6r)-2-carboxylato-4-hydroxy-6-[(2r,3s,4r,5r,6s)-4-hydroxy-6-methoxy-5-(sulfonatoamino)-2-(sulfonatooxymethyl)oxan-3-yl]oxy-5-sulfonatooxyoxan-3-yl]oxy-5-(sulfonatoamino)-4-sulfonatooxy-2-(sul Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].O[C@@H]1[C@@H](NS([O-])(=O)=O)[C@@H](OC)O[C@H](COS([O-])(=O)=O)[C@H]1O[C@H]1[C@H](OS([O-])(=O)=O)[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](OS([O-])(=O)=O)[C@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O[C@@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](COS([O-])(=O)=O)O4)NS([O-])(=O)=O)[C@H](O3)C([O-])=O)O)[C@@H](COS([O-])(=O)=O)O2)NS([O-])(=O)=O)[C@H](C([O-])=O)O1 XEKSTYNIJLDDAZ-JASSWCPGSA-D 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 229960004072 thrombin Drugs 0.000 description 6
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 5
- 229920000669 heparin Polymers 0.000 description 5
- 229940127215 low-molecular weight heparin Drugs 0.000 description 5
- 230000015271 coagulation Effects 0.000 description 4
- 238000005345 coagulation Methods 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 208000032843 Hemorrhage Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 208000007536 Thrombosis Diseases 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 208000034158 bleeding Diseases 0.000 description 3
- 230000000740 bleeding effect Effects 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000002537 thrombolytic effect Effects 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910001413 alkali metal ion Inorganic materials 0.000 description 1
- 229910001420 alkaline earth metal ion Inorganic materials 0.000 description 1
- 230000001858 anti-Xa Effects 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000001913 cellulose Chemical class 0.000 description 1
- 229920002678 cellulose Chemical class 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 238000002615 hemofiltration Methods 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 230000017570 negative regulation of blood coagulation Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008107 starch Chemical class 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7024—Esters of saccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- External Artificial Organs (AREA)
- Saccharide Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Materials For Medical Uses (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP97201586 | 1997-05-27 | ||
| PCT/EP1998/003174 WO1998053829A1 (en) | 1997-05-27 | 1998-05-22 | Use of oligosaccharide for preventing blood clotting in extracorporeal blood circuits |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO995800D0 NO995800D0 (no) | 1999-11-26 |
| NO995800L NO995800L (no) | 1999-11-26 |
| NO325142B1 true NO325142B1 (no) | 2008-02-11 |
Family
ID=8228366
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19995800A NO325142B1 (no) | 1997-05-27 | 1999-11-26 | Anvendelse av oligosakkarid for fremstilling av et medikament for forhindring av blodkoagulering i ekstra korporlige blodkretser |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US6391339B1 (pt) |
| EP (2) | EP0984785B1 (pt) |
| JP (2) | JP2002503270A (pt) |
| AT (1) | ATE307596T1 (pt) |
| AU (1) | AU8211398A (pt) |
| BR (1) | BR9809478A (pt) |
| CA (1) | CA2289522A1 (pt) |
| DE (1) | DE69832066T2 (pt) |
| DK (1) | DK0984785T3 (pt) |
| ES (1) | ES2251090T3 (pt) |
| NO (1) | NO325142B1 (pt) |
| WO (1) | WO1998053829A1 (pt) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE307596T1 (de) * | 1997-05-27 | 2005-11-15 | Sanofi Aventis | Verwendung eines oligosaccharids zur vorbeugung von blutgerinnung in extrakorporale kreisläufe |
| FR2804328B1 (fr) | 2000-01-27 | 2002-03-15 | Hospal Ind | Membrane semi-permeable non thrombogene et procede de fabrication |
| JP2006096668A (ja) * | 2002-11-08 | 2006-04-13 | Ono Pharmaceut Co Ltd | エラスターゼ阻害剤と血液凝固系および／または線溶系酵素阻害剤との組み合わせからなる医薬 |
| CA2782311C (en) * | 2009-12-01 | 2017-06-27 | Robert S. Ward | Method for removing cytokines from blood with surface immobilized polysaccharides |
| ES2647577T3 (es) | 2012-06-13 | 2017-12-22 | Exthera Medical Corporation | Uso de heparina y carbohidratos para tratar el cáncer |
| CA2928866C (en) | 2013-11-08 | 2021-11-09 | Exthera Medical Corporation | Methods for diagnosing infectious diseases using adsorption media |
| CA2946294C (en) | 2014-04-24 | 2023-03-21 | Exthera Medical Corporation | Method for removing bacteria from blood using high flow rate |
| US11911551B2 (en) | 2016-03-02 | 2024-02-27 | Exthera Medical Corporation | Method for treating drug intoxication |
| CN113825517A (zh) | 2019-05-16 | 2021-12-21 | 艾克塞拉医疗公司 | 调节内皮糖萼结构的方法 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2002A (en) * | 1841-03-12 | Tor and planter for plowing | ||
| DE3008993A1 (de) * | 1980-03-08 | 1981-10-01 | Röhm Pharma GmbH, 6100 Darmstadt | Pharmazeutische zubereitungen |
| US4331697A (en) * | 1980-09-02 | 1982-05-25 | Teijin Limited | Novel heparin derivative, method for production thereof, and method for rendering biomedical materials antithrombotic by use of the novel heparin derivative |
| US4818816A (en) * | 1981-04-28 | 1989-04-04 | Choay, S.A. | Process for the organic synthesis of oligosaccharides and derivatives thereof |
| US4987223A (en) * | 1981-12-23 | 1991-01-22 | Choay S.A. | Derivatives of the uronic acid |
| AU563351C (en) * | 1982-01-15 | 2003-06-19 | Glaxo Group Limited | Synthesis of oligosaccharides |
| US4801583A (en) * | 1982-01-15 | 1989-01-31 | Choay S.A. | Oligosaccharides and their biological applications |
| JPS63218691A (ja) * | 1987-03-09 | 1988-09-12 | Rikagaku Kenkyusho | 新規な５糖類化合物及びその製造法並びに抗凝血及び抗血栓剤 |
| EP0300099A1 (en) * | 1987-07-20 | 1989-01-25 | Akzo N.V. | New pentasaccharides |
| US5256559A (en) * | 1988-03-04 | 1993-10-26 | Biogen, Inc. | Methods and compositions for inhibiting platelet aggregation |
| US5252213A (en) * | 1989-06-20 | 1993-10-12 | University Of Washington | Dry dialysate composition |
| US5378829A (en) * | 1990-04-23 | 1995-01-03 | Akzo N.V. | Sulfated glycosaminoglycanoid derivatives of the heparin and heparan sulfate type |
| WO1993005825A1 (en) * | 1991-09-20 | 1993-04-01 | Baxter International Inc. | Processes for reducing the thrombogenicity of biomaterials |
| ITPD940054A1 (it) * | 1994-03-23 | 1995-09-23 | Fidia Advanced Biopolymers Srl | Polisaccaridi solfatati |
| US6391369B1 (en) * | 1996-03-27 | 2002-05-21 | Bunge Foods Corporation | Selectively hydrogenated high oleic oil compositions and process |
| IL120722A (en) * | 1996-05-08 | 1999-07-14 | Akzo Nobel Nv | Polysulfated tetrasaccharide derivatives and pharmaceutical compositions containing them |
| ATE307596T1 (de) * | 1997-05-27 | 2005-11-15 | Sanofi Aventis | Verwendung eines oligosaccharids zur vorbeugung von blutgerinnung in extrakorporale kreisläufe |
-
1998
- 1998-05-22 AT AT98932096T patent/ATE307596T1/de active
- 1998-05-22 EP EP98932096A patent/EP0984785B1/en not_active Expired - Lifetime
- 1998-05-22 DE DE69832066T patent/DE69832066T2/de not_active Expired - Lifetime
- 1998-05-22 JP JP50025099A patent/JP2002503270A/ja active Pending
- 1998-05-22 CA CA002289522A patent/CA2289522A1/en not_active Abandoned
- 1998-05-22 ES ES98932096T patent/ES2251090T3/es not_active Expired - Lifetime
- 1998-05-22 BR BR9809478-5A patent/BR9809478A/pt not_active Application Discontinuation
- 1998-05-22 EP EP05015221A patent/EP1593380A3/en not_active Withdrawn
- 1998-05-22 AU AU82113/98A patent/AU8211398A/en not_active Abandoned
- 1998-05-22 US US09/424,626 patent/US6391339B1/en not_active Expired - Lifetime
- 1998-05-22 DK DK98932096T patent/DK0984785T3/da active
- 1998-05-22 WO PCT/EP1998/003174 patent/WO1998053829A1/en active IP Right Grant
-
1999
- 1999-11-26 NO NO19995800A patent/NO325142B1/no not_active IP Right Cessation
-
2001
- 2001-11-02 US US10/005,793 patent/US20020040012A1/en not_active Abandoned
-
2006
- 2006-08-14 US US11/464,259 patent/US20070197637A1/en not_active Abandoned
-
2009
- 2009-08-25 JP JP2009193834A patent/JP2010013455A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2010013455A (ja) | 2010-01-21 |
| AU8211398A (en) | 1998-12-30 |
| DE69832066D1 (de) | 2005-12-01 |
| ES2251090T3 (es) | 2006-04-16 |
| EP1593380A3 (en) | 2008-06-11 |
| NO995800D0 (no) | 1999-11-26 |
| CA2289522A1 (en) | 1998-12-03 |
| DK0984785T3 (da) | 2006-01-30 |
| BR9809478A (pt) | 2000-06-20 |
| US20070197637A1 (en) | 2007-08-23 |
| WO1998053829A1 (en) | 1998-12-03 |
| EP0984785A1 (en) | 2000-03-15 |
| US20020040012A1 (en) | 2002-04-04 |
| NO995800L (no) | 1999-11-26 |
| US6391339B1 (en) | 2002-05-21 |
| EP1593380A2 (en) | 2005-11-09 |
| DE69832066T2 (de) | 2006-07-13 |
| JP2002503270A (ja) | 2002-01-29 |
| ATE307596T1 (de) | 2005-11-15 |
| EP0984785B1 (en) | 2005-10-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20070197637A1 (en) | Use of oligosaccharide for preventing blood clotting in extracorporeal blood circuits | |
| Holmer et al. | Heparin and its low molecular weight derivatives: anticoagulant and antithrombotic properties | |
| JP2703582B2 (ja) | 透析装置 | |
| US5801162A (en) | Dermatan sulfate compositions and antithrombotic compositions containing same | |
| Wolf | Low-molecular-weight heparin | |
| JPS6357407B2 (pt) | ||
| Ryan et al. | Dose finding study of a low molecular weight heparin, Innohep, in haemodialysis | |
| Ryan et al. | Antithrombotic properties of dermatan sulphate (MF 701) in haemodialysis for chronic renal failure | |
| JP2000300661A (ja) | 抗凝固剤／滅菌剤組成物と方法 | |
| Ireland et al. | Low molecular weight heparin in haemodialysis for chronic renal failure: dose finding study of CY222 | |
| Moriniere et al. | Low-molecular-weight heparin Fraxiparin® in chronic hemodialysis: a dose-finding study | |
| Thomas et al. | Low molecular weight heparin: A better drug | |
| MXPA99010965A (en) | Use of oligosaccharide for preventing blood clotting in extracorporeal blood circuits | |
| US20030092671A1 (en) | Antithrombotic composition | |
| Verstraete | Heparin and thrombosis: a seventy year long story | |
| Oguma et al. | Clinical effect of low molecular weight heparin (fragmin) on DIC: a multicenter cooperative study in Japan | |
| AU2001291549A1 (en) | Antithrombotic compositions | |
| Losito et al. | Molecular Weight of Heparin Versus Biologic Activity Some Additional Considerations | |
| Tosukowong et al. | Pharmacokinetics of Intravenous Fraxiparine in Thai Healthy Controls and Thai Chronic | |
| Prandoni | Current status of the clinical use of heparin fractions | |
| Krupinski et al. | in the Management of Thrombotic Disorders | |
| Petitou et al. | A new generation of antithrombotics based on synthetic oligosaccharides | |
| EP1321152A1 (en) | Antidote for org 31540/SR 90107A | |
| JPH10251153A (ja) | アスピリンおよび抗−Ｘａオリゴ糖の組合せを含有する組成物ならびにアスピリンと任意的に組み合わせた抗−Ｘａオリゴ糖の使用 | |
| AU2002333202A1 (en) | Antithrombotic compositions comprising low molecular wieght heparin and low molecular weight dermatan sulphate |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK1K | Patent expired |